Tarsus Pharmaceuticals, Inc. TARS Operating Loss Carryforwards
Operating Loss Carryforwards at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLossCarryforwards.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating loss carryforwards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s operating loss carryforwards?
- Tarsus Pharmaceuticals, Inc. (TARS) reported operating loss carryforwards of $176.1M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s operating loss carryforwards changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s operating loss carryforwards increased by 27.1% year-over-year, from $138.5M to $176.1M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s operating loss carryforwards?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s operating loss carryforwards has grown at a 47.4% compound annual growth rate (CAGR), from $25.3M to $176.1M.